248 related articles for article (PubMed ID: 33623382)
1. In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection.
Minooei F; Fried JR; Fuqua JL; Palmer KE; Steinbach-Rankins JM
Int J Nanomedicine; 2021; 16():1189-1206. PubMed ID: 33623382
[TBL] [Abstract][Full Text] [Related]
2. Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.
Chaowanachan T; Krogstad E; Ball C; Woodrow KA
PLoS One; 2013; 8(4):e61416. PubMed ID: 23630586
[TBL] [Abstract][Full Text] [Related]
3. pH-responsive delivery of Griffithsin from electrospun fibers.
Tyo KM; Duan J; Kollipara P; Dela Cerna MVC; Lee D; Palmer KE; Steinbach-Rankins JM
Eur J Pharm Biopharm; 2019 May; 138():64-74. PubMed ID: 29698714
[TBL] [Abstract][Full Text] [Related]
4. Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.
Tyo KM; Lasnik AB; Zhang L; Mahmoud M; Jenson AB; Fuqua JL; Palmer KE; Steinbach-Rankins JM
J Control Release; 2020 May; 321():84-99. PubMed ID: 32035194
[TBL] [Abstract][Full Text] [Related]
5. Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection.
Grooms TN; Vuong HR; Tyo KM; Malik DA; Sims LB; Whittington CP; Palmer KE; Matoba N; Steinbach-Rankins JM
Antimicrob Agents Chemother; 2016 Nov; 60(11):6518-6531. PubMed ID: 27550363
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
Jiang Y; Cao S; Bright DK; Bever AM; Blakney AK; Suydam IT; Woodrow KA
Mol Pharm; 2015 Dec; 12(12):4363-74. PubMed ID: 26529558
[TBL] [Abstract][Full Text] [Related]
7. Design of Poly(lactic-
Yang H; Li J; Patel SK; Palmer KE; Devlin B; Rohan LC
Pharmaceutics; 2019 Apr; 11(4):. PubMed ID: 30995761
[TBL] [Abstract][Full Text] [Related]
8. Rapid-Release Griffithsin Fibers for Dual Prevention of HSV-2 and HIV-1 Infections.
Tyo KM; Lasnik AB; Zhang L; Jenson AB; Fuqua JL; Palmer KE; Steinbach-Rankins JM
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229493
[TBL] [Abstract][Full Text] [Related]
9. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component.
O'Keefe BR; Vojdani F; Buffa V; Shattock RJ; Montefiori DC; Bakke J; Mirsalis J; d'Andrea AL; Hume SD; Bratcher B; Saucedo CJ; McMahon JB; Pogue GP; Palmer KE
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6099-104. PubMed ID: 19332801
[TBL] [Abstract][Full Text] [Related]
10. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide.
Emau P; Tian B; O'keefe BR; Mori T; McMahon JB; Palmer KE; Jiang Y; Bekele G; Tsai CC
J Med Primatol; 2007 Aug; 36(4-5):244-53. PubMed ID: 17669213
[TBL] [Abstract][Full Text] [Related]
11. Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.
Férir G; Palmer KE; Schols D
Virology; 2011 Sep; 417(2):253-8. PubMed ID: 21802104
[TBL] [Abstract][Full Text] [Related]
12. Antiviral lectin Q-Griffithsin suppresses fungal infection in murine models of vaginal candidiasis.
Nabeta HW; Lasnik AB; Fuqua JL; Wang L; Rohan LC; Palmer KE
Front Cell Infect Microbiol; 2022; 12():976033. PubMed ID: 36329822
[TBL] [Abstract][Full Text] [Related]
13. Preformulation Characterization of Griffithsin, a Biopharmaceutical Candidate for HIV Prevention.
Kramzer LF; Hamorsky KT; Graebing PW; Wang L; Fuqua JL; Matoba N; Lasnik AB; Moncla BJ; Zhang J; Palmer KE; Rohan LC
AAPS PharmSciTech; 2021 Feb; 22(3):83. PubMed ID: 33625602
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.
Date AA; Shibata A; Goede M; Sanford B; La Bruzzo K; Belshan M; Destache CJ
Antiviral Res; 2012 Dec; 96(3):430-6. PubMed ID: 23041201
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of silk fibroin biomaterial vehicle for in vivo mucosal delivery of Griffithsin and protection against HIV and SHIV infection ex vivo.
Crakes KR; Herrera C; Morgan JL; Olstad K; Hessell AJ; Ziprin P; LiWang PJ; Dandekar S
J Int AIDS Soc; 2020 Oct; 23(10):e25628. PubMed ID: 33073530
[TBL] [Abstract][Full Text] [Related]
16. Impact of Q-Griffithsin anti-HIV microbicide gel in non-human primates: In situ analyses of epithelial and immune cell markers in rectal mucosa.
Günaydın G; Edfeldt G; Garber DA; Asghar M; Noȅl-Romas L; Burgener A; Wählby C; Wang L; Rohan LC; Guenthner P; Mitchell J; Matoba N; McNicholl JM; Palmer KE; Tjernlund A; Broliden K
Sci Rep; 2019 Dec; 9(1):18120. PubMed ID: 31792342
[TBL] [Abstract][Full Text] [Related]
17. Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel.
Teleshova N; Keller MJ; Fernández Romero JA; Friedland BA; Creasy GW; Plagianos MG; Ray L; Barnable P; Kizima L; Rodriguez A; Cornejal N; Melo C; Cruz Rodriguez G; Mukhopadhyay S; Calenda G; Sinkar SU; Bonnaire T; Wesenberg A; Zhang S; Kleinbeck K; Palmer K; Alami M; O'Keefe BR; Gillevet P; Hur H; Liang Y; Santone G; Fichorova RN; Kalir T; Zydowsky TM
PLoS One; 2022; 17(1):e0261775. PubMed ID: 35051209
[TBL] [Abstract][Full Text] [Related]
18. Role of the carbohydrate-binding sites of griffithsin in the prevention of DC-SIGN-mediated capture and transmission of HIV-1.
Hoorelbeke B; Xue J; LiWang PJ; Balzarini J
PLoS One; 2013; 8(5):e64132. PubMed ID: 23741304
[TBL] [Abstract][Full Text] [Related]
19. Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus.
Levendosky K; Mizenina O; Martinelli E; Jean-Pierre N; Kizima L; Rodriguez A; Kleinbeck K; Bonnaire T; Robbiani M; Zydowsky TM; O'Keefe BR; Fernández-Romero JA
Antimicrob Agents Chemother; 2015 Dec; 59(12):7290-8. PubMed ID: 26369967
[TBL] [Abstract][Full Text] [Related]
20. The role of individual carbohydrate-binding sites in the function of the potent anti-HIV lectin griffithsin.
Xue J; Gao Y; Hoorelbeke B; Kagiampakis I; Zhao B; Demeler B; Balzarini J; Liwang PJ
Mol Pharm; 2012 Sep; 9(9):2613-25. PubMed ID: 22827601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
